FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia

Moxetumomab pasudotox is a CD22-directed cytotoxin or immunotoxin and is a first-in-class type of treatment for patients with HCLFDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news